Lars Bastholt

Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort.

Journal: Immuno-oncology technology

Published: September 05, 2026

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 21, 2026

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 21, 2026

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 19, 2026

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Journal: Journal of the National Cancer Institute

Published: March 09, 2026

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Journal: International journal of cancer

Published: January 28, 2026

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 23, 2025

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Journal: Journal of the National Cancer Institute

Published: June 24, 2025

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Journal: British journal of cancer

Published: February 12, 2025

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 23, 2025

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma.

Journal: Journal of autoimmunity

Published: January 20, 2025

Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort.

Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort.

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Sentinel node biopsy and survival in cutaneous melanoma: a nationwide population-based cohort study.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma.

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond.

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma.

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.